My research 'saim is to identify new therapeutic targets, disease mechanisms, novel biomarkers to stratify patients with precision medicine. Currently, I am investigating acute myeloid leukaemia (AML)’s metabolic dependency and how to exploit this distinctive metabolic reprogramming for novel therapeutics. Understanding oncometabolism is crucial because cancer cells undergo significant metabolic reprogramming to support their rapid growth and proliferation. Metabolic pathways that are dysregulated in cancer cells provide a unique opportunity todevelop targeted therapies that specifically target cancer cells without affecting normal cells. Additionally, oncometabolism research has the potential to identify novel biomarkers for cancer diagnosis and prognosis. By studying oncometabolism, we can uncover the mechanisms that allow cancer cells to sustain their growth, evade the immune system, and become resistant to therapy.This knowledge can inform the development of new treatments that target the metabolic vulnerabilities of cancer cells, leading to improved outcomes for cancer patients.